Modified C-ring (except Methyl In 13-position) (e.g., Double Bond Containing, Substituted, Etc.) Patents (Class 514/179)
-
Patent number: 8846652Abstract: A steroid derivative compound of formula (I) in which: one of R1 and R2 is hydroxy and the other is hydrogen; or R1 and R2 together represent oxo; R3 is hydrogen or hydroxy; and the dotted lines represent single or double carbon-carbon bonds; and pharmaceutically acceptable salts and esters thereof are useful for the prevention or treatment of pain, for improving nerve regeneration after nerve injury or damage or disease, for the prevention or treatment of brain injury, damage or disease and for neuroprotection. Particularly useful compounds are 11-hydroxy-?4-androstene-3,17-dione and 11-oxo-?4-androstene-3,17-dione or their derivatives.Type: GrantFiled: November 17, 2006Date of Patent: September 30, 2014Assignee: Hunter-Fleming LimitedInventors: Ernst Wulfert, James Robert Murray, David Wynick
-
Publication number: 20140287030Abstract: In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from Pentalinon andrieuxii. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: OHIO STATE INNOVATION FOUNDATIONInventors: Abhay R. Satoskar, James R. Fuchs, Alan Douglas Kinghorn, Li Pan, Claudio M. Lezama-Davila, Eric Bachelder
-
Publication number: 20140287052Abstract: The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to paediatric treatment regimens, the treatment of the elderly and non-human animals.Type: ApplicationFiled: November 19, 2012Publication date: September 25, 2014Applicant: Diurnal LimitedInventors: Hiep Huatan, Richard Ross, Martin Whitaker
-
Publication number: 20140287027Abstract: The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, the liposomes comprising a non-charged vesicle-forming lipid, and optionally an amphipathic vesicle-forming lipid and/or a negatively charged vesicle-forming lipid. The invention further relates to a new pharmaceutical composition suitable for treating cancer, and especially solid primary and secondary tumors.Type: ApplicationFiled: May 28, 2014Publication date: September 25, 2014Applicant: Enceladus Pharmaceuticals B.V.Inventors: Raymond Michel Schiffelers, Josbert Maarten Metselaar, Grietje Molema, Gerrit Storm
-
Publication number: 20140286884Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.Type: ApplicationFiled: March 18, 2014Publication date: September 25, 2014Applicant: LUROMED LLCInventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
-
Publication number: 20140274985Abstract: The present disclosure provides a method for treating dry eye syndrome that comprises systemically administering to a patient in need thereof an effective amount of an androgen, including transdermal or subcutaneous delivery of the androgen.Type: ApplicationFiled: March 7, 2014Publication date: September 18, 2014Inventors: Raman Malhotra, Matthew Long
-
Publication number: 20140271867Abstract: The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MONOSOL RX, LLCInventor: Garry L. Myers
-
Publication number: 20140274936Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: SYNTHONICS, INC.Inventors: Thomas Piccariello, John D. Price, Robert A. Oberlender, Michaela E. Mulhare, Mary C. Spencer, Scott B. Palmer
-
Publication number: 20140271819Abstract: Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: STEFAN PRONIUK
-
Publication number: 20140256696Abstract: The present invention describes steroid conjugates. These single drug entities are formed by connecting two or more steroids via a linker. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual steroid drugs.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: Allergan, Inc.Inventors: Santosh C. Sinha, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
-
Publication number: 20140256660Abstract: The present invention describes novel single drug entities, formed by the linkage of an antibiotic with a steroidal drug via a linker. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: Allergan, Inc.Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
-
Publication number: 20140256690Abstract: A transdermal drug delivery device for reducing the risk of pregnancy in overweight women is disclosed. Methods of using the device are also disclosed. When used in accordance with the disclosed methods, the probability that the device will be effective in overweight women is approximately equal to or greater than the probability that the device would be effective in the case of a woman who is not overweight.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: AGILE THERAPEUTICS, INC.Inventors: Arkady RUBIN, Maria FOEGH, Agis KYDONIEUS, Thomas M. ROSSI
-
Patent number: 8828428Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.Type: GrantFiled: April 16, 2014Date of Patent: September 9, 2014Assignee: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides
-
Publication number: 20140242167Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.Type: ApplicationFiled: April 17, 2014Publication date: August 28, 2014Applicant: DuoCort Pharma ABInventors: Stanko SKRTIC, Jörgen JOHNSSON, Hans LENNERNÄS, Thomas HEDNER, Gudmundur JOHANNSSON
-
Publication number: 20140243299Abstract: Described herein are methods and compositions for increasing the bioavailability of a corticosteroid, such as hydrocortisone 17-butyrate, in a topical formulation.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: Precision Dermatology, Inc.Inventors: Ronald M. Gurge, Mark W. Trumbore, Pinaki R. Majhi
-
Publication number: 20140243300Abstract: Described are methods and compositions for tuning the bioavailability of an active agent, such as a corticosteroid, in a topical formulation.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: Precision Dermatology, Inc.Inventors: Mark W. Trumbore, Pinaki R. Majhi, Neha Aggarwal
-
Publication number: 20140235602Abstract: The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.Type: ApplicationFiled: April 11, 2014Publication date: August 21, 2014Applicant: REPROS THERAPEUTICS INC.Inventor: Joseph S. Podolski
-
Publication number: 20140235603Abstract: The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible.Type: ApplicationFiled: April 24, 2014Publication date: August 21, 2014Applicant: LABORATOIRE HRA-PHARMAInventor: Richard Hausknecht
-
Publication number: 20140234225Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: February 17, 2014Publication date: August 21, 2014Applicant: Alkermes Pharma Ireland LimitedInventors: Christian F. Wertz, Niels P. Ryde
-
Patent number: 8809350Abstract: The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.Type: GrantFiled: May 4, 2012Date of Patent: August 19, 2014Assignee: Cyclacel LimitedInventors: Ariela Benigni, Carla Zoja, Giuseppe Remuzzi, Athos Gianella-Borradori
-
Publication number: 20140228335Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicant: Laboratoire HRA PHARMAInventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
-
Patent number: 8802133Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.Type: GrantFiled: July 13, 2012Date of Patent: August 12, 2014Assignee: Advanced Bio-Technologies, Inc.Inventor: Paul Guilbaud
-
Patent number: 8796248Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.Type: GrantFiled: October 3, 2008Date of Patent: August 5, 2014Assignee: Nektar TherapeuticsInventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
-
Publication number: 20140213532Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidine or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.Type: ApplicationFiled: December 24, 2013Publication date: July 31, 2014Applicant: KAI PHARMACEUTICALS, INC.Inventors: Jonathan B. Rothbard, Paul A. Wender, Leo P. McGrane, Lalitha V.S. Sista, Thorsten A. Kirschberg
-
Patent number: 8791096Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.Type: GrantFiled: May 17, 2005Date of Patent: July 29, 2014Assignee: Norton Healthcare LtdInventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
-
Patent number: 8790691Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.Type: GrantFiled: May 26, 2009Date of Patent: July 29, 2014Assignee: The University of British ColumbiaInventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
-
Patent number: 8785425Abstract: The invention provides 11?-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: wherein R4 represents a moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C), Z is S:Type: GrantFiled: July 25, 2008Date of Patent: July 22, 2014Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Jiten Ranchhodbhai Patel, Gopalkumar Chimanlal Patel, Gaurav Sanjivkumar Sheth, Samir Rameshchandra Shah, Sanjay Nandlal Mandhane, Trinadha Rao Chitturi, Rajamannar Thennati
-
Patent number: 8784877Abstract: Described are transdermal drug delivery systems for the transdermal administration of levonorgestrel, comprising a polymer matrix and levonorgestrel acetate. Methods of making and using such systems also are described.Type: GrantFiled: December 27, 2011Date of Patent: July 22, 2014Assignee: Noven Pharmaceuticals, Inc.Inventors: David W. Houze, Vincent Lau Chan
-
Patent number: 8784882Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: July 29, 2011Date of Patent: July 22, 2014Assignee: Mattern Pharma AGInventor: Claudia Mattern
-
Patent number: 8785426Abstract: Described are gel compositions containing active pharmaceutical ingredient such as testosterone, solvent, and thickener, the gel compositions being useful for transdermal administration of the active ingredient to a patient, and related methods. Certain embodiments of the gel composition specifically exclude Hsieh enhancer.Type: GrantFiled: February 11, 2014Date of Patent: July 22, 2014Assignee: Upsher-Smith Laboratories, Inc.Inventor: Harish K. Pimplaskar
-
Publication number: 20140193517Abstract: Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second pharmaceutical intended for treatment of said at least one disease or disorder; determining an association strength between the drug-side effect (SE) association and the disease-side effect (SE) association; selecting said at least one disease or disorder as a new therapeutic indication for said at least one first pharmaceutical if said at least one first pharmaceutical induces at least one side effect which is the same as at least one side effect induced by at least one second pharmaceutical intended for treatment of said at least one disease or disorder.Type: ApplicationFiled: August 17, 2012Publication date: July 10, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Pankaj Agarwal, Lun Yang
-
Publication number: 20140186279Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: CAMURUS ABInventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
-
Publication number: 20140187525Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: ApplicationFiled: March 7, 2014Publication date: July 3, 2014Applicants: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, LABORATOIRE HRA-PHARMAInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Publication number: 20140186341Abstract: The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Inventor: Martin L. Mayse
-
Publication number: 20140187481Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: ApplicationFiled: July 3, 2013Publication date: July 3, 2014Inventors: Arthur Tudor Tucker, Nigel Benjamin
-
Patent number: 8759330Abstract: Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the ?-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity.Type: GrantFiled: August 20, 2010Date of Patent: June 24, 2014Assignee: Washington UniversityInventors: Douglas F. Covey, Xin Jiang
-
Publication number: 20140171490Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.Type: ApplicationFiled: August 9, 2013Publication date: June 19, 2014Applicant: PHARMALINGT INC.Inventors: Yossi Gross, Rafi Herzog, Steven B. Koevary
-
Publication number: 20140162993Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.Type: ApplicationFiled: October 29, 2013Publication date: June 12, 2014Applicant: Corcept TherapeuticsInventor: Joseph K. Belanoff
-
Publication number: 20140162992Abstract: The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals.Type: ApplicationFiled: June 12, 2013Publication date: June 12, 2014Inventor: Edward Dunne Corboy, JR.
-
Publication number: 20140154306Abstract: 17?,21-Dihydroxypregna-4,9-diene-3,20-dione and 17?,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.Type: ApplicationFiled: December 11, 2013Publication date: June 5, 2014Applicant: COSMO S.P.A.Inventors: Mauro AJANI, Luigi MORO
-
Publication number: 20140147464Abstract: A method for inducing autophagy in a subject having an autophagy defect is provided. The method of the present invention includes the step of administering to the subject a therapeutically effective amount of a Ganoderma lucidum extract, wherein the autophagy enhances clearance of protein aggregates in the subject.Type: ApplicationFiled: November 26, 2012Publication date: May 29, 2014Applicant: NATIONAL YANG-MING UNIVERSITYInventors: Rong-Tsun Wu, Lin-Yea Horng, Hui-Ching Sung, Li-Wen Chen
-
Patent number: 8735381Abstract: The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. In certain embodiments, the invention provides a method for suppressing endometrial proliferation.Type: GrantFiled: April 2, 2013Date of Patent: May 27, 2014Assignee: Repros Therapeutics Inc.Inventor: Joseph S. Podolski
-
Patent number: 8735380Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.Type: GrantFiled: December 8, 2009Date of Patent: May 27, 2014Assignee: Laboratoire HRA PharmaInventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
-
Publication number: 20140142077Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.Type: ApplicationFiled: March 1, 2013Publication date: May 22, 2014Applicants: Laboratories Besins International, SAS, Unimed Pharmaceuticals, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratories Besins International, SAS
-
Publication number: 20140142078Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: ReveraGen BiopharmaInventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
-
Publication number: 20140135298Abstract: This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for treating cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, particularly for expanding the efficacy of drugs previously developed for this purpose, and for methods of treatments using the compounds for this purpose.Type: ApplicationFiled: March 16, 2012Publication date: May 15, 2014Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Alan Berezov, Mark I. Greene, Natalie Minkovsky, Zheng Cai, Hongtao Zhang
-
Publication number: 20140135302Abstract: Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: SOMALOGIC, INC.Inventors: Malti P. Nikrad, Stuart G. Field, Stephen Alaric Williams, Alex A.E. Stewart, Rachel M. Ostroff, Rosalynn Dianne Gill
-
Publication number: 20140127278Abstract: The present invention relates to the treatment of vascular disease in a diabetic patient using a drug-eluting implantable medical device that releases everolimus from three distinctly loaded drug reservoir layers wherein at least one of the layers comprises at least 200 ?g/cm2 of everolimus and further wherein the everolimus is the only therapeutic agent in the layers or the layers or any combination thereof further comprise an anti-inflammatory agent or an RGD peptide or both.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.Inventor: Syed F.A. Hossainy
-
Publication number: 20140128329Abstract: Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: Allergan, Inc.Inventors: Anuradha V. Gore, Chetan P. Pujara, Richard S. Graham, Melissa Gulmezian, Kristin Prinn, Ramakrishnan Srikumar
-
Publication number: 20140109916Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 27, 2013Publication date: April 24, 2014Applicant: Bayer Intellectual Property GmbHInventors: Thomas LANGGUTH, Stefan BRACHT, Michael DITTGEN, Petra HUBER, Dirk SCHENK